Human Apyrase Therapy for Diabetic Neuropathic Pain
Human Apyrase Therapy for Diabetic Neuropathic Pain
批准号:
8976658
负责人:
RIDONG CHEN
金额:
$29.98万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-08-01 至 2017-01-31
关键词:
AddressAdenosineAdjuvantAdverse effectsAffectAgonistAnalgesicsAnimal ModelAnimalsAnticonvulsantsAntidepressive AgentsApyraseAttenuatedBehavioralBiological AssayBlood GlucoseBlood VesselsBolus InfusionClinical TrialsDataDiabetic NeuropathiesDiseaseDoseExhibitsFamilyGoalsHormonesHumanHyperglycemiaInflammationInflammatoryInjection of therapeutic agentLidocaineMechanicsModelingNerveNeuropathyNociceptionNon-Insulin-Dependent Diabetes MellitusNorepinephrineOpioid AnalgesicsP2X-receptorPainPathway interactionsPatientsPhasePrincipal InvestigatorProstate carcinomaQuality of lifeRattusRefractoryReportingSafetySerotoninSignal TransductionStreptozocinSuraminSymptomsTactileTestingTherapeutic IndexTramadolUnited StatesWeight GainWorkaddictionallodyniachronic constriction injurydb/db mousediabeticduloxetineextracellularfunctional statusgabapentinimprovedinflammatory paininhibitor/antagonistnerve injuryneurotransmissionnovelpain behaviorpainful neuropathypreclinical safetypregabalinprogramsprostatic fraction Acid phosphatase isoenzymepublic health relevancereceptorresponsereuptakespared nervetransmission process
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Neuropathic pain such as diabetic neuropathic pain (DNP) can be difficult to treat with only 30-40% of patients achieving meaningful (>40-50%) pain relief. Current therapies (e.g. duloxeline) mainly address symptoms by focusing on blocking neurotransmission in the pain pathway with limited efficacy, potentially severe side effects and narrow therapeutic index. Hence, novel therapies are needed to safely manage symptoms and also target the underlying pathophysiological mechanisms that will improve the functional status and life quality of affected patients. APT102, an optimized human apyrase, selectively scavenges excess pro-inflammatory and algogenic extracellular ATP (eATP) and ADP (eADP) and metabolizes them to eAMP, thereby attenuating vascular or central inflammation and pain. Ubiquitous CD73 further metabolizes eAMP to adenosine, which has been shown to reduce neuropathic pain in animals and humans. It has been shown that administration of APT102 exhibited a long-lasting (days) anti-hyperalgesic effect in the model of Complete Freud's Adjuvant-induced inflammatory pain with no noticeable side effects. In the proposed studies, we will evaluate the dose-response of APT102 in both the chronic constriction injury (CCI) model of neuropathy and the model of STZ-induced diabetic neuropathy. We also will determine the potential side effects of APT102 using the rotarod and functional observational battery assays in healthy rats. Specific Aim 1. To determine whether APT102 (s.c.) will abrogate neuropathic pain in the CCI model in rats without behavioral side effects. Specific Aim 2. To determine whether APT102 (s.c.) will abrogate neuropathic pain in the STZ-induced diabetic model in rats without significant side effects. The long-term goal is to develop APT102 as a safe and disease-modifying analgesic therapy. Weekly or monthly dosing will provide sustained pain relief for neuropathic pain patients without significant side effects, tolerance or addiction.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Multi-functional anti-thrombotic therapy for coronary microvascular obstruction
-
批准号:10696319
-
项目类别:
-
资助金额:$158.2万
-
财政年份:2023
-
负责人:RIDONG CHEN
-
依托单位:
Peripherally Acting Analgesic for Osteoarthritis Pain
-
批准号:10249564
-
项目类别:
-
资助金额:$25.96万
-
财政年份:2021
-
负责人:RIDONG CHEN
-
依托单位:
Synergistic Efficacy of an Interleukin 2 Analog and Antitumor Antigen Antibody
-
批准号:9905448
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2019
-
负责人:RIDONG CHEN
-
依托单位:
Immunomodulatory Therapy for Neuropathic Pain
-
批准号:10684821
-
项目类别:
-
资助金额:$50.13万
-
财政年份:2018
-
负责人:RIDONG CHEN
-
依托单位:
Immunomodulatory Therapy for Neuropathic Pain
-
批准号:10490450
-
项目类别:
-
资助金额:$92.25万
-
财政年份:2018
-
负责人:RIDONG CHEN
-
依托单位:
Immunomodulatory Therapy for Neuropathic Pain
-
批准号:10378231
-
项目类别:
-
资助金额:$99.64万
-
财政年份:2018
-
负责人:RIDONG CHEN
-
依托单位:
IL2-based Immunotherapy for Type 2 Diabetes
-
批准号:9135661
-
项目类别:
-
资助金额:$29.92万
-
财政年份:2016
-
负责人:RIDONG CHEN
-
依托单位:
IL2-based Immunotherapy for Lupus
-
批准号:9253700
-
项目类别:
-
资助金额:$22.5万
-
财政年份:2016
-
负责人:RIDONG CHEN
-
依托单位:
Low-dose IL-2-based Immunomodulatory Therapy for PAH
-
批准号:8829630
-
项目类别:
-
资助金额:$29.74万
-
财政年份:2015
-
负责人:RIDONG CHEN
-
依托单位:
Manufacturing of Growth Factors to Enable Cardiopoietic Stem Cell Therapy for Hea
-
批准号:8766958
-
项目类别:
-
资助金额:$22.41万
-
财政年份:2014
-
负责人:RIDONG CHEN
-
依托单位:
optimized Human Apyrase for Bone Cancer Pain Treatment
-
批准号:8589871
-
项目类别:
-
资助金额:$28.83万
-
财政年份:2013
-
负责人:RIDONG CHEN
-
依托单位:
Prevention of Vein Graft Intimal Hyperplasia with Optimized Human Apyrase
-
批准号:8391881
-
项目类别:
-
资助金额:$28.16万
-
财政年份:2012
-
负责人:RIDONG CHEN
-
依托单位:
Combination Therapy of Aspirin and Apyrase for Stroke
-
批准号:7996413
-
项目类别:
-
资助金额:$28.76万
-
财政年份:2010
-
负责人:RIDONG CHEN
-
依托单位:
Adjunctive Use of Apyrase to Fibrinolytic Therapy
-
批准号:8315704
-
项目类别:
-
资助金额:$72.96万
-
财政年份:2009
-
负责人:RIDONG CHEN
-
依托单位:
Adjunctive Use of Apyrase to Fibrinolytic Therapy
-
批准号:7744087
-
项目类别:
-
资助金额:$22.61万
-
财政年份:2009
-
负责人:RIDONG CHEN
-
依托单位:
Adjunctive Use of Apyrase to Fibrinolytic Therapy
-
批准号:8520381
-
项目类别:
-
资助金额:$57.78万
-
财政年份:2009
-
负责人:RIDONG CHEN
-
依托单位:
Human Apyrase to Disrupt Cancer Therapy
-
批准号:7599772
-
项目类别:
-
资助金额:$19.67万
-
财政年份:2008
-
负责人:RIDONG CHEN
-
依托单位:
Combination Treatment of tPA and Apyrase for Stroke
-
批准号:7904542
-
项目类别:
-
资助金额:$61.22万
-
财政年份:2007
-
负责人:RIDONG CHEN
-
依托单位:
Apyrase to Treat Ischemia/Reperfusion Injury during Lung Transplantation
-
批准号:7218419
-
项目类别:
-
资助金额:$18.96万
-
财政年份:2007
-
负责人:RIDONG CHEN
-
依托单位:
Apyrase to treat ischemia/reperfusion injury during lung transplantation
-
批准号:7778848
-
项目类别:
-
资助金额:$43.91万
-
财政年份:2007
-
负责人:RIDONG CHEN
-
依托单位:
国内基金
海外基金
基于ADK/Adenosine调控DNA甲基化探讨“利湿化瘀通络”法对2型糖尿病肾病足细胞裂孔膜损伤的干预机制研究
-
批准号:82074359
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2020
-
负责人:安晓飞
-
依托单位:
细胞外腺苷(Adenosine)作为干细胞旁分泌因子的生物学鉴定和功能分析
-
批准号:81570244
-
项目类别:面上项目
-
资助金额:57.0万元
-
批准年份:2015
-
负责人:丁兆平
-
依托单位:
Adenosine诱导A1/A2AR稳态失衡启动慢性低灌注白质炎性损伤及其机制
-
批准号:81171113
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2011
-
负责人:黄文
-
依托单位: